正常前列腺18F-FDG PET/CT显像的FDG摄取研究

摘要
图/表
参考文献(20)
相关文章 (15)

全文: PDF (510 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨正常前列腺18F-FDG PET/CT显像中的放射性摄取范围及其影响因素。方法回顾性分析2014年11月~2016年1月于北京医院因非前列腺疾病而行18F-FDG PET/CT全身显像的男性患者83例，年龄20~91岁，平均（60±18）岁。分析其PET/CT图像的影像学特征。采用感兴趣区（ROI）技术获得前列腺最大及平均FDG标准化摄取值（SUV）即SUVmax及SUVavg，并在最大横断层面测定前列腺直径。采用SPSS 17.0统计软件包对前列腺SUVmax、SUVavg与患者的年龄及前列腺大小行Pearson相关性分析。结果正常前列腺SUVmax平均值为2.3±0.4，SUVavg平均值为1.6±0.3，前列腺直径平均值为（4.4±0.7）cm。前列腺大小与年龄呈正相关关系（r=0.365，P < 0.05），而前列腺SUV值（SUVmax及SUVavg）与年龄、前列腺大小无显著相关关系（P > 0.05）。结论正常前列腺体积随着年龄增长而增加，但其在18F-FDG PET/CT上的FDG摄取值并不受年龄及前列腺大小的影响。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈雯张建飞刘秀芹

关键词 ：前列腺, 体层摄影术, 发射型计算机, 脱氧葡萄糖

Abstract：Objective To determine the FDG uptake of the normal prostate gland with 18F-FDG PET/CT imaging and its influence factors. Methods The normal prostates in 83 men detected by 18F-FDG PET/CT imaging in Beijing Hospital from November 2014 to January 2016 were analyzed retrospectively, aged 20-91, average of (60±18) years. Their PET/CT imaging characteristics were analyzed. ROI technology was used for getting the SUVmax and SUVavg, and the diameters of prostate gland were detected in the maximum shear plane. Correlations among the SUV, prostate size and age were analyzed by Pearson correlation analysis with SPSS 17.0. Results The average of SUV maximum and mean was (2.3±0.4) and (1.6±0.3) respectively. The average of normal prostate gland size was (4.4±0.7) cm. There was positive correlation between prostate size and age (r=0.365, P < 0.05), but there was no statistically significant relationship between the SUV (SUVmax and SUVavg) and the size of normal prostate gland (P > 0.05), the SUV (SUVmax and SUVavg) of the prostate gland was not significantly related with age also (P > 0.05). Conclusion The prostate gland size get larger as age increased, but the age and the size are not influence the FDG uptake of the prostate gland with 18F-FDG PET/CT imaging.

Key words： Prostete gland Tomography Emission-computed Deoxyglucose

基金资助:北京医院博士启动基金（BJ-2015-110）。

作者简介: 陈雯（1981.2-），女，博士；研究方向：临床核医学。

引用本文:

陈雯张建飞刘秀芹. 正常前列腺18F-FDG PET/CT显像的FDG摄取研究[J]. 中国医药导报, 2017, 14(16): 102-105.
CHEN Wen ZHANG Jianfei LIU Xiuqin. The FDG uptake of the normal prostate gland with 18F-FDG PET/CT imaging. 中国医药导报, 2017, 14(16): 102-105.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2017/V14/I16/102

[1] Grant K，Lindenberg ML，Shebel H，et al. Functional and molecular imaging of localized and recurrent prostate cancer [J]. Eur J Nucl Med Mol Imaging，2013，40（1）：48-59.
[2] Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT：utility and limitations [J]. Eur J Nucl Med Mol Imaging，2013，40（Suppl 1）：5-10.
[3] Yang ZY，Hu SL，Cheng JY，et al. Prevalence and risk of cancer of incidental uptake in prostate identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography [J]. Clin Imaging，2014，38（4）：470-474.
[4] Vaz CV，Marques R，Alves MG，et al. Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1，GLUT3，PFK，LDH and MCT4 genes [J]. J Cancer Res Clin Oncol，2016，142（1）：5-16.
[5] Macheda ML，Rogers S，Best JD. Molecular and cellular regulation of glucose transporter（GLUT）proteins in cancer [J]. J Cell Physiol，2005，202（3）：654-662.
[6] Stewardt GD，Gray K，Pennington CJ，et al. Analysis of hypoxia-associated gene expression in prostate cancer：lysyl oxidase and glucose transporter-1 expression correlate with Gleason score [J]. Oncol Rep，2008，20（6）：1561-1567.
[7] Takahashi N，Inoue T，Lee J，et al. The roles of PET and PET/CT in the diagnosis and management of prostate cancer [J]. Oncology，2007，72（3-4）：226-233.
[8] Von MD，Backhaus B，Muller SC，et al. Technical limits of PET/CT with 18FDG in prostate cancer [J]. Aktuelle Urol，2006，37（3）：218-221.
[9] Wilkinson C，Chowdhury F，Scarsbrook A，et al. BCG-induced granulomatous prostatitis-an incidental finding on FDG PET-CT [J]. Clin Imaging，2012，36（4）：413-415.
[10] Minamimoto R，Uemura H，Sano，et al. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level [J]. Ann Nucl Med， 2011，25（1）：21-27.
[11] Yu CY，Desai B，Ji LY，et al. Comparative performance of PET tracers in biochemical recurrence of prostate cancer：a critical analysis of literature [J]. Am J Nucl Med Mol Imaging，2014，4（6）：580-601.
[12] 林美福，周硕，陈文新，等.18F-FDG 18F-FECH双示踪剂PET/CT在前列腺癌诊疗中的应用[J].福建医科大学学报，2012，46（5）：366-369.
[13] Patel AR，Jones JS，Rabets J，et al. Parasagittal biopsies add minimal information in repeat saturation prostate biopsy [J]. Urology，2004，63（1）：87-89.
[14] Schoder H，Herrmann K，Gonen M，et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for detection of disease in patients with prostatespecific antigen relapse after radical prostatectomy [J]. Clin Cancer Res，2005，11（13）：4761-4769.
[15] Meirelles GS，Schoder H，Ravizzini GC，et al. Prognostic value of baseline fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer [J]. Clin Cancer Res，2010，16（24）：6093-6099.
[16] Jadvar H，Desai B，Ji L，et al. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer [J]. Clin Nucl Med，2012，37（7）：637-643.
[17] ■ztürk H，Karapolat I. 18F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer [J]. Oncol Lett，2016，11（1）：316-322.
[18] Wang Y，Chiu R，Rosenberg J，et al. Standardized uptake value atlas： characterization of physiological 2-deoxy-2-[18F]fluoro-D-glucose uptake in normal tissues [J]. Mol Imaging Biol，2007，9（2）：83–90.
[19] Jadvar H，Ye W，Groshen S，et al. [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland [J]. Ann Nucl Med，2008，22（9）：787-793.
[20] Turlakow A，Larson SM，Coakley F，et al. Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose： comparison of filtered back projection and iterative reconstruction with segmented attenuation correction [J]. Q J Nucl Med，2001，45（3）：235-244.